Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Altimmune (ALT) over the last 13 years, with Sep 2025 value amounting to $5.8 million.

  • Altimmune's Other Non-Current Liabilities rose 22188.46% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 22188.46%. This contributed to the annual value of $5.3 million for FY2024, which is 13225.00% up from last year.
  • Latest data reveals that Altimmune reported Other Non-Current Liabilities of $5.8 million as of Q3 2025, which was up 6.70% from $5.4 million recorded in Q2 2025.
  • Altimmune's Other Non-Current Liabilities' 5-year high stood at $7.0 million during Q3 2021, with a 5-year trough of $16,000 in Q1 2025.
  • For the 3-year period, Altimmune's Other Non-Current Liabilities averaged around $2.1 million, with its median value being $38,500 (2023).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 99.01% in 2022, then spiked by 22,188.46% in 2025.
  • Over the past 5 years, Altimmune's Other Non-Current Liabilities (Quarterly) stood at $6.1 million in 2021, then tumbled by 99.01% to $60,000 in 2022, then tumbled by 33.33% to $40,000 in 2023, then surged by 13,225.00% to $5.3 million in 2024, then soared by 22,188.46% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $5.4 million for Q2 2025, and $16,000 during Q1 2025.